Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80 [Yahoo! Finance]
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
Company Research
Source: Yahoo! Finance
This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis. We maintain our Buy-Venture rating and have adjusted our target price to $12.80 per share, reflecting confidence in Quantum BioPharma's pioneering efforts in addressing brain disorders and alcohol health. The Company's strong pipeline includes Lucid-MS, targeting progressive Multiple Sclerosis, and unbuzzd™, a formulation designed to expedite alcohol metabolism. With marketing experts Kevin Harrington and Gerry David leading unbuzzd™'s market launch, Quantum BioPharma is positioned for substantial growth. For access to our research report on Quantum BioPharma, please click here For more information on Quantum BioPharma, visit www.QuantumBioPharma.com For more information on Singular Research, visit www.SingularResearch
Show less
Read more
Impact Snapshot
Event Time:
QNTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNTM alerts
High impacting Quantum Biopharma Ltd. - Class B Subordinate Voting Shares news events
Weekly update
A roundup of the hottest topics
QNTM
News
- Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in AustraliaAccesswire
- Christian Attar Files Market Manipulation Case On Behalf of Quantum BiopharmaPR Newswire
- Freedman Normand Friedland Files Market Manipulation Case On Behalf of Quantum BiopharmaPR Newswire
- Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/SpoofingAccesswire
- Shark Tank Judge Invests In All-Natural Alcohol Detox Beverage [Forbes]Forbes
QNTM
Sec Filings
- 11/12/24 - Form 6-K
- 10/29/24 - Form 6-K
- 10/22/24 - Form 6-K
- QNTM's page on the SEC website